All In Biotech

NDA 020215 · Omnivium Pharms

Monoket

Isosorbide Mononitrate · Oral · Nitrate Vasodilator

Last checked: Nov 20, 2026Latest source record: Feb 1, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Jun 30, 1993

Approved uses

1

Original approval plus efficacy supplements

Registered trials

88

18 Phase 3, 4 recruiting

FAERS reports

20,958

17,559 serious, 2,621 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 5, 2025.

INDICATIONS AND USAGE: Isosorbide Mononitrate Tablets are indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 30, 1993 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • MONOKET · ISOSORBIDE MONONITRATE 20MG · TABLET, ORAL · Prescription · TE AB
  • MONOKET · ISOSORBIDE MONONITRATE 10MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Isosorbide Mononitrate" as an intervention, any sponsor and status, largest first.

All 88 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,592
  • dizziness1,487
  • diarrhoea1,331
  • fatigue1,328
  • nausea1,301
  • chest pain1,239
  • headache1,095
  • myocardial infarction1,074
  • vomiting998
  • hypotension960
  • off label use951
  • malaise947

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004456
2005540
2006517
2007396
2008616
2009518
2010455
2011661
2012820
2013533
2014858
20151,022
20161,162
20171,198
20181,477
20191,416
20201,179
2021973
20221,266
20231,527
20241,154
20251,256
2026953

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 189 on PubMed

Sponsor: Omnivium Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.